Abstract
Disease-modifying therapies such as transthyretin (TTR) gene-silencing drugs and TTR tetramer stabilizers have been developed for hereditary transthyretin (ATTR) amyloidosis, a major type of autosomal dominant hereditary amyloidosis. Recently, a second-generation TTR gene-silencing drug, vutrisiran, was approved for treating patients with hereditary ATTR amyloidosis in Japan. This new drug significantly reduced the patient's physical burden.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.